Torasemide, a long-acting loop diuretic, reduces the progression of myocarditis to dilated cardiomyopathy.

[1]  T. Suzuki,et al.  Effects of torasemide on cardiac sympathetic nerve activity and left ventricular remodelling in patients with congestive heart failure , 2006, Heart.

[2]  H. Schultheiss,et al.  Myocardial proteases and matrix remodeling in inflammatory heart disease. , 2006, Cardiovascular research.

[3]  F. Pinto,et al.  BNP and ANP as diagnostic and predictive markers in heart failure with left ventricular systolic dysfunction , 2004, Journal of the renin-angiotensin-aldosterone system : JRAAS.

[4]  Arantxa González,et al.  Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure. , 2004, Journal of the American College of Cardiology.

[5]  G. Christensen,et al.  Elevated Levels of Activin A in Heart Failure: Potential Role in Myocardial Remodeling , 2004, Circulation.

[6]  M. Uechi,et al.  The effects of the loop diuretics furosemide and torasemide on diuresis in dogs and cats. , 2003, The Journal of veterinary medical science.

[7]  K. Weber,et al.  Aldosteronism in heart failure: a proinflammatory/fibrogenic cardiac phenotype. Search for biomarkers and potential drug targets. , 2003, Current drug targets.

[8]  M. Yamato,et al.  Effects of torasemide on left ventricular function and neurohumoral factors in patients with chronic heart failure. , 2003, Circulation journal : official journal of the Japanese Circulation Society.

[9]  C. Delcayre,et al.  Molecular mechanisms of myocardial remodeling. The role of aldosterone. , 2002, Journal of molecular and cellular cardiology.

[10]  Arantxa González,et al.  Regulation of myocardial fibrillar collagen by angiotensin II. A role in hypertensive heart disease? , 2002, Journal of molecular and cellular cardiology.

[11]  K. Wagner,et al.  Transgenic overexpression of the sarcoplasmic reticulum Ca2+ ATPase improves reticular Ca2+ handling in normal and diabetic rat hearts , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[12]  J. Díez,et al.  Torasemide in chronic heart failure: results of the TORIC study , 2002, European journal of heart failure.

[13]  T. Masuda,et al.  Aldosterone synthase (CYP11B2) expression and myocardial fibrosis in the failing human heart. , 2002, Clinical science.

[14]  M. Horie,et al.  Torasemide inhibits transcardiac extraction of aldosterone in patients with congestive heart failure. , 2002, Journal of the American College of Cardiology.

[15]  Melissa M Deer,et al.  Open-label randomized trial of torsemide compared with furosemide therapy for patients with heart failure. , 2001, The American journal of medicine.

[16]  J. Díez,et al.  Effects of loop diuretics on angiotensin II-stimulated vascular smooth muscle cell growth. , 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[17]  C. Roberts,et al.  Natriuretic peptide signalling: molecular and cellular pathways to growth regulation. , 2001, Cellular signalling.

[18]  KazuwaNakao,et al.  Aldosterone Production Is Activated in Failing Ventricle in Humans , 2001 .

[19]  Kenichi Watanabe,et al.  Low dose carvedilol inhibits progression of heart failure in rats with dilated cardiomyopathy , 2000, British journal of pharmacology.

[20]  J. Díez,et al.  Torasemide inhibits angiotensin II-induced vasoconstriction and intracellular calcium increase in the aorta of spontaneously hypertensive rats. , 1999, Hypertension.

[21]  A. Carayon,et al.  , Brigitte Angiotensin II Receptor Blockade and Role in Cardiac Fibrosis Activation of Cardiac Aldosterone Production in Rat Myocardial Infarction : Effect of , 1999 .

[22]  C. Napoli,et al.  Loop diuretics enhance the secretion of prostacyclin in vitro, in healthy persons, and in patients with chronic heart failure , 1999, European Journal of Clinical Pharmacology.

[23]  A. Goertz,et al.  COMPARISON OF THERAPIES WITH TORASEMIDE OR FUROSEMIDE IN PATIENTS WITH CONGESTIVE HEART FAILURE FROM A PHARMACOECONOMIC VIEWPOINT , 1998, International journal of clinical practice.

[24]  T. Goodfriend,et al.  Torsemide inhibits aldosterone secretion in vitro. , 1998, Life sciences.

[25]  C. Delcayre,et al.  Myocardial Production of Aldosterone and Corticosterone in the Rat , 1998, The Journal of Biological Chemistry.

[26]  J. Kult,et al.  High-dose torasemide, given once daily intravenously for one week, in patients with advanced chronic renal failure. , 1997, Clinical Nephrology.

[27]  F. Müller,et al.  Messenger RNA expression and immunological quantification of phospholamban and SR-Ca(2+)-ATPase in failing and nonfailing human hearts. , 1996, Cardiovascular research.

[28]  A J Tajik,et al.  Two-Dimensional and Doppler Echocardiography Alone Can Adequately Define Preoperative Anatomy and Hemodynamic Status before Repair of Complete Atrioventricular Septal Defect in Infants <1 Year Old , 1994, Circulation.

[29]  J. H. Patterson,et al.  Oral Torsemide in Patients With Chronic Congestive Heart Failure: Effects on Body Weight, Edema, and Electrolyte Excretion , 1994, Pharmacotherapy.

[30]  M. Kodama,et al.  Rat dilated cardiomyopathy after autoimmune giant cell myocarditis. , 1994, Circulation research.

[31]  L. J. McCutcheon,et al.  Compensatory downregulation of myocardial Ca channel in SR from dogs with heart failure. , 1993, The American journal of physiology.

[32]  J. S. Janicki,et al.  Myocardial fibrosis: functional significance and regulatory factors. , 1993, Cardiovascular research.

[33]  P. A. Zwieten.  Comparative mechanisms of action of diuretic drugs in hypertension , 1992 .

[34]  H. Kido,et al.  Anti-aldosteronergic effect of torasemide. , 1991, European journal of pharmacology.

[35]  K. Hayashi,et al.  EFFECTS OF TORASEMIDE ON RENAL HAEMODYNAMICS AND FUNCTION IN ANAESTHETIZED DOGS , 1991, Clinical and experimental pharmacology & physiology.

[36]  K. Weber,et al.  Pathological Hypertrophy and Cardiac Interstitium: Fibrosis and Renin‐Angiotensin‐Aldosterone System , 1991, Circulation.

[37]  M. Kodama,et al.  A novel experimental model of giant cell myocarditis induced in rats by immunization with cardiac myosin fraction. , 1990, Clinical immunology and immunopathology.

[38]  J. Gwathmey,et al.  Abnormal intracellular calcium handling, a major cause of systolic and diastolic dysfunction in ventricular myocardium from patients with heart failure. , 1990, Circulation.

[39]  R. Greger,et al.  Torasemide inhibits NaCl reabsorption in the thick ascending limb of the loop of Henle , 1986, Pflügers Archiv.

[40]  K. Yamaguchi.  Effects of water deprivation on immunoreactive angiotensin II levels in plasma, cerebroventricular perfusate and hypothalamus of the rat. , 1981, Acta endocrinologica.

[41]  P. Wangemann,et al.  Analogues of torasemide — structure function relationships —experiments in the thick ascending limb of the loop of Henle of rabbit nephron , 2004, Pflügers Archiv.

[42]  G. Berry,et al.  Pathology of Human Myocarditis , 2003 .

[43]  L. Cooper.  Myocarditis : from bench to bedside , 2003 .

[44]  H. Kido,et al.  Diuretic and vasodilating actions of torasemide. , 1994, Cardiology.

[45]  H. Kido,et al.  Diuretic profile of a novel loop diuretic torasemide in rats and dogs. , 1991, Drugs under experimental and clinical research.

[46]  R. Greger.  Inhibition of active NaCl reabsorption in the thick ascending limb of the loop of Henle by torasemide. , 1988, Arzneimittel-Forschung.

[47]  G. Laurent,et al.  Dynamic state of collagen: pathways of collagen degradation in vivo and their possible role in regulation of collagen mass. , 1987, The American journal of physiology.

[48]  J. Denef,et al.  Renal effects of the high ceiling diuretic torasemide in rats and dogs. , 1985, Arzneimittel-Forschung.

[49]  M. Gerin,et al.  Pharmacological properties of the new potent diuretic torasemide in rats and dogs. , 1985, Arzneimittel-Forschung.